Abstract Objective: The purpose of the study was to study the distribution of poor and extensive metabolizers of CYP2C19 and CYP2D6 and to genotype for CYP2C8 and CYP2C9 among 312 randomly selected Faroese. Methods and results: The participants were phenotyped for CYP2D6 with the use of sparteine. The distribution of the sparteine metabolic ratio (sparteine/didehydrosparteines) was bimodal, and 14.5% (n=44; 95% CI: 10.7-18.9%) of the subjects were phenotyped as poor metabolizers. The frequency of poor metabolizers was higher (P=0.0002; v 2 test) among the Faroese than in other European populations (7.4%). Genotype analyses for the CYP2D6*3, *4, *6 and *9 alleles were performed using real-time polymerase chain reaction (PCR) (TaqMan, Foster City, CA, USA), and we found 14.6% (n = 45) (95% CI: 10.8-19.0%) with deficient CYP2D6 genes (*3/*4, *4/*4, *4/*6, *6/*6) in the Faroese population. The subjects were phenotyped for CYP2C19 with the use of mephenytoin and 10 subjects, i.e., 3.2% (95% CI: 1.6-5.9%) were phenotyped as poor metabolizers. Genotype analysis for the CYP2C19*2 and *3 alleles was performed by means of PCR analysis, and 2.9% (n=9) (95% CI: 1.3-5.4%) of the Faroese were found to have a deficient CYP2C19 gene all explained by the CYP2C19*2/*2 genotype. The allele frequencies of the CYP2C9*2 and CYP2C9*3 alleles were 8.8% (95% CI: 6.7-11.4%) and 5.3% (95% CI: 3.7-7.4%), respectively, while the CYP2C8*3 allele frequency was 6.9% (95% CI: 5.0-9.2%). Real-time PCR (TaqMan) was used for both CYP2C9 and CYP2C8 genotype analyses. Conclusion: The frequency of CYP2D6 poor metabolizers is twofold higher among the Faroese population than other Caucasians, while the frequencies of Faroese subjects with decreased CYP2C19, CYP2C8 and CYP2C9 enzyme activity are the same as seen in other Caucasian populations. A possible consequence might be a higher incidence of side effects among Faroese patients taking pharmaceuticals that are CYP2D6 substrates.
Introduction
The polymorphisms of CYP2D6 and CYP2C19 are relatively well known, and more than 80 mutations of the CYP2D6 gene and about 15 mutations of the CYP2C19 gene have been described [1] . More than 75 drugs are metabolized by CYP2D6, including antidepressants, selective serotonin reuptake inhibitors and opioids [2] . The CYP2C19 metabolizes more than 25 drugs including proton pump inhibitors and some antidepressants [3] . Populations in different environments and with different genetic backgrounds show interethnic differences in drug metabolism [4] . Geographical differences in the metabolism of sparteine (CYP2D6) and also S-mephenytoin (CYP2C19) are well known. The CYP2D6 poor metabolizers (PMs) represent 5-10% of Caucasians [5] and 0-2% of African and Orientals [6, 7] . The frequency of CYP2C19 PMs varies from approximately 3% in Caucasians and Africans to 13-23% in Orientals [4] . Genetic polymorphisms have also been identified for CYP2C8 that oxidizes drugs such as taxol, cerivastatin, as well as endobiotics such as retinoic acid and arachidonic acid [8] . The most frequent allele associated with defective metabolism is the CYP2C8*3 allele, which occurs with a frequency of 13% in Caucasians and 2% in AfroAmericans [9] . The polymorphic CYP2C9 enzyme is responsible for the metabolism of several commonly used drugs, including S-warfarin, phenytoin and the nonsteroidal anti-inflammatory drugs [10] . The CYP2C9*2 allele has been found in 11-13% of Caucasians and 1-4% of Africans, while it is not present in Orientals [11] . A single nucleotide polymorphism (SNP) linkage disequilibrium between the CYP2C8 and CYP2C9 genes has been reported. According to Yasar et al. [12] , 96% of the subjects with CYP2C8*3 alleles also carried CYP2C9*2 alleles, while 85% of the subjects genotyped as CYP2C9*2 also were genotyped as CYP2C8*3.
The Faroe Islands include 18 islands situated northwest of Scotland and halfway between Iceland and Norway.
The Faroese population derives mainly from Vikings of predominantly Norse extraction, who settled in the Faroe Islands in the ninth century [13, 14] . However, an influx of men and women from the British Isles, either as independent colonisers or brought there by Vikings, may have contributed significantly to the current gene pool of the Faroese population [15] . It has been suggested that the Faroes were populated by Irish monks or hermits as early as 650 A.D. and they may have left before the Norse settlement [16] .
Genetic studies of the Faroese population are limited, but increased incidence of diseases associated with specific gene mutations are known, presumably due to founder effects [17] , isolation, inbreeding or simply genetic drift. Examples of diseases are glycogen storage disease type IIIA (GSD IIIA) [18] , hereditary hemochromatosis (HFE) [19] , cystic fibrosis (CF) [20] , primary ciliary dyskinesia [17] and classical non-AIDSrelated Kaposi's sarcoma [21] .
According to the findings cited above, it is likely that the Faroese population is of Nordic origin, but in some aspects genetically different from other Caucasian populations. Hence, we were interested in studying the activity of the important drug metabolizing enzymes CYP2D6 and CYP2C19, as well as the occurrence of variant alleles within the CYP2D6, CYP2C19, CYP2C9 and CYP2C8 genes, among Faroese subjects.
Methods

Subjects
From the Faroese national register we received the names of 900 randomly selected Faroese individuals between 18 years and 60 years, which was the inclusion criteria. Approximately one-third was excluded based on the following criteria: concomitant medication, pregnancy or breastfeeding and allergy to medicine. Onethird refused to participate for various reasons. Hence, 312 healthy Faroese (144 females and 168 males) were recruited. The mean age of the participants was 39 years. All subjects consented to participate on the basis of verbal and written information in Faroese. The study was approved by the Faroese Ethics Committee.
Of the 312 volunteers, eight individuals were excluded from the sparteine test: two women were excluded from the phenotyping part because of uncertain pregnancy status, but blood samples were taken for genotype analysis. Further, the analysis of the urine from four persons showed that they had not ingested the sparteine capsule, even though they had collected urine. For two subjects, the urine volume was not recorded and consequently these two persons were therefore excluded. In total, 304 persons were included in the CYP2D6 phenotype analysis.
The two possibly pregnant women were also excluded from the mephenytoin test. Thereby, 310 persons were included in the CYP2C19 phenotype analysis.
For the CYP2D6, CYP2C19, CYP2C8 and CYP2C9 genotype analysis, one person was excluded because it was not possible to get a blood sample from him. He was however included in the phenotype analysis. Two samples could not be genotyped for CYP2D6, either due to homozygosity for the CYP2D6*5 allele or poor quality of DNA, and were excluded from the genotype analyses. Consequently, 311 samples were genotyped for CYP2C19, CYP2C8 and CYP2C9, and 309 for CYP2D6.
Phenotyping
After emptying the bladder the participants took an oral dose of 100 mg racemic mephenytoin (Mesantoin, Sandoz Pharmaceuticals Corporation, East Hanover, NJ, USA) and 100 mg sparteinesulphate pentahydrate (The Central Pharmacy, Odense University Hospital, Denmark). They also received 200 mg caffeine at the same time due to participation in another study on CYP1A2. It has been demonstrated that the simultaneous administration of a low dose of these drugs does not influence the outcome of their respective metabolic indices [22, 23] . Urine was collected from 0 h to 12 h after dosing. The total volume was recorded, and aliquots of 2·10 ml were stored at À80°C until analysis. Sparteine, 2,3-didehydrosparetine and 5,6-didehydrosparetine in urine (% of dose) was assayed by gas chromatography [24] . The metabolic ratio (MR) was calculated as:
in the urine at 12 h.
Individuals with a sparteine MR greater than 14 were classified as PMs. Historically the antimode between PMs and extensive metabolizers (EMs) is 20, but this is an arbitrary value and, scientifically, no better founded than, for instance, 14. Inspection of the data from the genotype analysis in this particular study encourages us to set an antimode of 14 instead of 20. In this manner, the phenotype results were analyzed accordingly with respect to genotype accordance. Three subjects with MR ratios below 20 (14.3, 14.5 and 18.9) had a CYP2D6-deficient genotype.
The ratio between S-mephenytoin and R-mephenytoin in the urine was determined using gas chromatography according to Wedlund et al. [25] , as modified by Sanz et al. [26] .
All urine samples with an S/R ratio greater than 0.5 were reanalyzed after acid treatment according to Tybring and Bertilsson [27] . In EMs the S/R ratio increases to several times the original value, whereas it remains the same in true PMs. Subjects having S/R ratios greater than 1, which did not increase significantly after acid treatment, were thus classified as PMs.
Genotyping
A 10-ml blood sample was drawn in Vacutainer tubes containing ethylene diamine tetraacetic acid (EDTA ) (BD, Franklin Lakes, NJ, USA), and the blood was immediately transferred to a DNA glass (Terumo Europe, Haasrode, Belgium) and kept frozen at À80°C until extraction of DNA for polymerase chain (PCR) analysis. The DNA was isolated using a PUREGENE genomic DNA purification kit by Gentra Systems, Minnesota 55441, USA. Genotype analyses for the CYP2D6*3, *4, *6 and *9 alleles were performed by means of PCR before using the Taqman technology. The real-time analysis was performed at the ABI PRISM 7700 Sequence Detection System equipped with the allelic discrimination module (software Version 1.7; Applied Biosystems, Foster City, CA, USA). Genotype analysis for the CYP2C19*2 and *3 alleles was performed as described previously [28, 29] . Primers and probes for CYP2D6 and CYP2C19 were purchased from Applied Biosystems.
The samples were also genotyped for the CYP2C9*2 and *3 alleles as well as the CYP2C8*3 allele. The methods used for genotyping CYP2C8*3 and CYP2C9*3 have previously been described [12] . For the CYP2C9*2 allele, new primers and probes, specific for the CYP2C9 gene, were designed (Tables 3 and 5 ), using Primer Express 1.0 from Applied Biosystems, Invitrogen (Paisley, Scotland, UK).
Primers and probes used in this study are summarized in Tables 1-3 .
Results
Among 304 Faroese subject phenotyped with sparteine, 44 had a MR ratio above 14 and were assigned as PMs. Thus, the incidence of CYP2D6 PMs was 14.5% (95% CI: 10.7-18.9%). The frequency of PMs was twofold higher (P=0.0002; v 2 test) among the Faroese than other European populations (7.4%) [5] . (Fig. 1) The MR ratio in the Faroese ranged from 0.10 to 230, and the frequency distribution in EMs and PMs of sparteine is shown in Fig. 2 .
By genotype analysis, the frequency of each of the CYP2D6*3, *4, *6 and *9 alleles was determined for 309 individuals, and a high frequency of the CYP2D6*4 MR ¼ % of dose sparteine % of dose 2,3 -didehydrosparteine þ % of dose 5,6 -didehydrosparteine Table 1 Sequence of oligonucleotide CYP2D6 primers and probes used in this study Sequence 5¢ fi 3¢ Primers CYP1 att tcc cag gaa tcc CYP4 ccg gcc ctg aca ctc ctt ct CYP2D6*3 sense tcc tga ccc agc tgg atg a CYP2D6*3 antisense ctt ctc cat ctc tgc cag gaa CYP2D6*4 sense cga ccc ctt acc cgc atc CYP2D6*4 antisense ctc acg gct ttg tcc aag aga CYP2D6*6 sense ctt ggg cct ggg caa ga CYP2D6*6 antisense agg gca gca caa agg ca CYP2D6*9 sense gag acc tga ctg agg cct tcc t CYP2D6*9 antisense tca ttc ctc ctg gga cgc t Probes CYP2D6*3 wtMGB FAM-tca tcc tgt gct cag tt-MGB CYP2D6*3 mutMGB VIC-tca tcc gtg ctc agt t-MGB CYP2D6*4 wt FAM-acc ccc agg acg ccc ctt t-tamra CYP2D6*4 mut JOE-acc ccc aag acg ccc ctt tc-tamra CYP2D6*6 wtMGB FAM-cgg tca ccc act gc-MGB CYP2D6*6 mutMGB VIC-cgg tca ccc ctg c-MGB CYP2D6*9 wtMGB FAM-tct cac ctt ctc cat ct-MGB CYP2D6*9 mutMGB VIC-tct cac ctc cat ctc-MGB Among 310 Faroese subjects phenotyped with mephenytoin, 18 individuals had an S/R ratio of 0.5 or greater, and they were all clearly classified as PMs or EMs after acid treatment and reanalysis of the samples, and 10 were assigned as PMs having an S/R ratio of 1 or more. The prevalence of PMs of S-mephenytoin in the population studied was therefore 3.2% (95% CI: 1.6-5.9%). Statistically, this frequency was not significantly different from other Europeans (P=0.80; v 2 test) [5] . The S/R ratio distribution in EMs and PMs of S-mephenytoin is presented in Fig. 3 .
Of the 10 PMs of CYP2C19, identified through the mephenytoin test, 9 were by the genotype analysis found to be homozygous for the CYP2C19*2 mutation. The last one was genotyped as CYP2C19*1/*2. This person had an S/R ratio of 1.18 before and 1.26 after acid treatment and were therefore by the phenotype analysis classified as a PM. The CYP2C19*3 mutation was not found in the Faroese population, and the frequency of subjects with CYP2C19 deficient genes was found to be 2.9% (95% CI: 1.3-5.4%).
The allele frequencies of CYP2C9*1, *2 and *3, and CYP2C8*1 and *3 were 86.7% (95% CI: 83.7-89.2%), 8.8% (95% CI: 6.7-11.4%), 5.3% (95% CI: 3.7-7.4%), 93.0 (95% CI: 90.8-95.0%) and 6.9% (95% CI: 5.0-9.2%), respectively. This is in agreement with previously reported allele frequencies in other Caucasians [30] .
About 95% (95% CI: 84.2-99.4%) of the subjects with CYP2C8*3 alleles also carried CYP2C9*2 alleles, while 75% (95% CI: 61.0-85.3%) of the subjects having the CYP2C9*2 variant also carried CYP2C8*3 alleles.
The results of the CYP2D6, CYP2C19, CYP2C9 and CYP2C8 genotyping in the Faroese population are summarized in Tables 4-7 . Table 3 Sequence of specific oligonucleotide primers and MGB-TaqMan probes used for the discrimination of the CYP2C9*2 alleles. Sequence of oligonucleotide CYP2C9*2 primers and probes used in this study and the discrimination between CYP2C9*1 and CYP2C9*3 have been described elsewhere [12] Primers Sequence 5¢ fi 3¢
Forward primer (CYP2C9*2) caa tgg aaa gaa atg gaa gga gat Reverse primer (CYP2C9*2) aag ata gta gtc cag taa ggt cag tga tat g Probe (for discriminationof CYP2C9*1) ttg aac acG gtc ctc Probe (for discrimination of CYP2C9*2) ttg aac acAa gtc ctc a Fig. 1 The position of the Faroe Islands
Discussion
This study is the first to estimate the distribution of CYP2D6 and CYP2C19 PMs and EMs and the distribution of CYP2C8 and CYP2C9 genotypes in the Faroese population. The observed frequency of CYP2D6 PMs is about 14% in Faroese subjects, which is about twice the frequency reported in other Caucasian populations. The reason for the high frequency of CYP2D6 PMs among Faroese is unknown but might be due to the geographical isolation of the Faroe Islands, giving rise to a genetically homogeneous population. The frequency of CYP2D6 PMs found by the phenotype analysis (14.5%) is slightly different from the frequency of subjects with CYP2D6-deficient genotypes found by the genotype analysis (14.6%). There are different reasons for this finding but they can all be explained.
One of the two women who did not ingest the sparteine capsule because of possible pregnancy was genotyped as CYP2D6*4/*4. Two of the four subjects whose urine analysis showed that they had not ingested the sparteine capsule also had a CYP2D6-deficient genotype. Further, 304 subjects were included in the CYP2D6 phenotype analysis while 309 were genotyped for CYP2D6. However, we consider the result demonstrates a concordance between the frequencies found by the phenotype and genotype analysis.
The CYP2D6 polymorphism has been studied as a risk factor for Parkinson's disease (PD), and a higher frequency of CYP2D6 PMs among PD patients has been reported [31, 32] . The number of PD patients is relatively higher on the Faroe Islands than in other countries Fig. 2 The distribution of sparteine metabolic ratios (MR) in 304 Faroese Fig. 3 The distribution of S-mephenytoin and R-mephenytoin ratios (S/R) in 310 Faroese [33] [34] [35] , and the frequency of CYP2D6 PMs is twice as high as in other Caucasians. Therefore, there may be an association between these two facts. Tricyclic antidepressants are metabolized by CYP2D6, which also catalyzes the metabolism of a number of other antidepressants [36, 37] . The PM phenotype and genotype may result in a very high plasma drug concentration and lead to side effects [38] . Hence, the high frequency of CYP2D6 PMs among Faroese presumably results in a, respectively, larger part of the population suffering from adverse effects when taking CYP2D6 substrates, especially tricyclic antidepressants than seen in other populations.
As a consequence of the high frequency of CYP2D6 PMs, the response rate to analgesic treatment with tramadol is probably decreased in several Faroese patients. Experimental pain studies have showed reduced efficacy of tramadol in PMs [39, 40] .
In conclusion, the frequency of CYP2D6 PMs is twofold higher in the Faroese population than in other Caucasians, while the frequencies of Faroese subjects with decreased CYP2C19, CYP2C8 and CYP2C9 enzyme activity are the same as seen in other Caucasian populations. Further studies of, for example, the association between PD and CYP2D6 PMs among Faroese are warranted. Attention to possible side effects of drug treatments in Faroese CYP2D6 PMs is needed. 
